



Project & Portfolio Value Creation



Course Leader **Dr. Richard Bayney** President & Founder of Project & Portoflio Value Creation

PROJECT, PROGRAM, AND PORTFOLIO RISK ANALYSIS CERTIFIED MASTERCLASS

MARCH 5-6, 2024 LONDON, UNITED KINGDOM

MASTERCLASS HIGHLIGHTS

Overview

Learn how to quantify and manage risk at project, program, and portfolio levels. Assess the extent to which multiple indications and/or lines of therapy affect program risk and valuation. Quantify the likelihood that your R&D pipeline portfolio and commercial portfolio will meet annual corporate targets.

Key Topics

- Quantification of project risk using risk decomposition and Decision Trees
- Quantification of program risk using correlated project risks and Decision Trees
- Quantification of portfolio risk using simulation
- Generation of strategic alternatives for Clinical
 Development, Registration, and Commercialization
- Selecting dominant strategies based on eNPV
- Accounting for commercial uncertainty in the product portfolio using simulation
- Accounting for risk and commercial uncertainty in the pipeline portfolio
- Quantifying the likelihood of meeting corporate growth targets (Long Range Plan)

Meet the Masterclass Leader

Dr. Richard Bayney is President of <u>Project & Portfolio Value</u> <u>Creation (PPVC)</u>, a consulting boutique that he founded in 2008 which provides training and education in Project, Program, Portfolio, Resource, and Risk Management as well as Business, Strategic, Portfolio, and Scenario Planning services. He is an adjunct faculty member at the University of Pennsylvania.

Dr. Bayney is a 23-year veteran of the Pharmaceutical & Biotechnology industry at Merck & Co., Bayer Corp. and AG, Bristol-Myers Squibb, and Johnson & Johnson Pharmaceutical Research & Development. In his previous position at Johnson & Johnson, Richard was Vice President, Portfolio Management & Decision Analysis. Dr. Bayney obtained his M.Sc. and Ph.D. from the University of London, MBA from Columbia University, and PMP from the Project Management Institute.

Features

- Real-time, instructor-led masterclass
- Live discussions
- Networking with participants
- Case studies & activities
- Individual consultancy with the trainer
- Colored hardcopy of training materials in a binder
- Electronic copy of trainer's textbook
- Certificate of completion issued by the trainer

Masterclass Audience

This masterclass is particularly interesting for industry professionals across involved in:

- Professionals involved in:
- Project, Program, Portfolio Management
- Research
- Clinical Development
- Resource Management
- Forecasting & Competitive Intelligence
- Finance
- Licensing & Business Development
- Commercialization



AGENDA



- 8:00 **1. Introduction** Agenda, background, goals; review of Risk Analysis survey
- 9:00 **2. Project Risk Analysis In Clinical Development** Risk decomposition – the key to quantifying uncontrollable risks and time-dependent controllable risks

Case Study I: Simulation analysis of pipeline throughput

Software Demo: Frontline Solver

10:00 COFFEE & TEA BREAK

10:20 **Case Study II:** Tracking concodrance between predicted success rates using risk decomposition and actual success rates

12:00 LUNCH BREAK

13:00 3. Project Risk Analysis In Discovery & Pre-Clinical Development





www.whysummits.com/masterclasses

WHY SUMMITS MASTERCLASS

3

AGENDA

MODULE 2 DAY 2 - MARCH 6, 2024

- 8:00 **5. Program Risk Analysis** Structuring multi-project programs to account for non-correlated and correlated risks
- 9:00 **6. Application of Program Risk Analysis to Decision Trees** Accounting for technical and commercial dependencies between projects
- 10:00 COFFEE & TEA BREAK

-

15:00

10:20 **Case Study VI:** Accounting for correlated risks between indications and lines of therapy in a program and selecting the dominant strategy with and without commercial uncertainty

Software: Frontline Solver

- 12:00 LUNCH BREAK
- 13:00 **7. Portfolio risk analysis** Defining, assessing, and displaying portfolio risk

14:00 8. Application of Simulation to Prtfolios of Commercial Products

Using simulation to incorporate uncertainty into the commercial portfolio of products

Case Study VII: Assessing the likelihood of meeting annual top line growth targets in the Long Range Commercial Plan (LRCP) with commercial uncertainty

Software: Frontline Solver

COFFEE & TEA BREAK



- 15:20 **9.** Application of Simulation to Portfolios of R&D
 - Projects

Case Study VIII: Assessing the likelihood of meeting annual top line growth targets in the Long Range R&D Plan (LRRDP) with risk and with/ without commercial uncertainty

Software: Palisade's @Risk

16:45 10. Wrap up Final Q&A

17:00 DAY 2 CLOSING REMARKS



MASTERCLASS + CONFERENCE MASTERCLASS CONFERENCE Grants access to the 25th European Grants access the Masterclass + Grants access to the Project, Program, and Conference at a special rate London, March 7-8 2024. London, March 5-6, 2024. from 3199 GBP from 2199 GBP from 2099 GBP æ Click above to Click above to Click above to learn more & register learn more & register learn more & register

www.whysummits.com/masterclasses

WHY SUMMITS MASTERCLASS

why@whysummits.com